ATE297214T1 - Behandlung von immunologischen und hematologischen störungen mit igfbp allein oder als komplex mit igf - Google Patents

Behandlung von immunologischen und hematologischen störungen mit igfbp allein oder als komplex mit igf

Info

Publication number
ATE297214T1
ATE297214T1 AT02002410T AT02002410T ATE297214T1 AT E297214 T1 ATE297214 T1 AT E297214T1 AT 02002410 T AT02002410 T AT 02002410T AT 02002410 T AT02002410 T AT 02002410T AT E297214 T1 ATE297214 T1 AT E297214T1
Authority
AT
Austria
Prior art keywords
igfbp
igf
complex
treatment
immunological
Prior art date
Application number
AT02002410T
Other languages
English (en)
Inventor
Joseph A Carlino
Howard R Higley
Christopher A Maack
Original Assignee
Celtrix Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharma filed Critical Celtrix Pharma
Application granted granted Critical
Publication of ATE297214T1 publication Critical patent/ATE297214T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT02002410T 1993-09-20 1994-09-20 Behandlung von immunologischen und hematologischen störungen mit igfbp allein oder als komplex mit igf ATE297214T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12441093A 1993-09-20 1993-09-20

Publications (1)

Publication Number Publication Date
ATE297214T1 true ATE297214T1 (de) 2005-06-15

Family

ID=22414706

Family Applications (2)

Application Number Title Priority Date Filing Date
AT94928166T ATE226958T1 (de) 1993-09-20 1994-09-20 Behandlung von hematologischen störungen mit einem igf-1/igfbp-3 komplex
AT02002410T ATE297214T1 (de) 1993-09-20 1994-09-20 Behandlung von immunologischen und hematologischen störungen mit igfbp allein oder als komplex mit igf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT94928166T ATE226958T1 (de) 1993-09-20 1994-09-20 Behandlung von hematologischen störungen mit einem igf-1/igfbp-3 komplex

Country Status (9)

Country Link
US (1) US5527776A (de)
EP (2) EP1238674B1 (de)
JP (1) JPH09507832A (de)
AT (2) ATE226958T1 (de)
AU (1) AU688793B2 (de)
CA (1) CA2172158A1 (de)
DE (2) DE69434403T2 (de)
ES (1) ES2241906T3 (de)
WO (1) WO1995008567A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728676A (en) * 1994-09-08 1998-03-17 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5869602A (en) * 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6436897B2 (en) * 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US6417330B1 (en) 1998-06-01 2002-07-09 Celtrix Pharmaceuticals, Inc. Insulin-like growth factor binding protein variants
EP1117425A2 (de) * 1998-10-02 2001-07-25 Celtrix Pharmaceuticals, Inc. Verfahren zur behandlung von nichtthyroidstörungen
US7288516B1 (en) 1999-09-20 2007-10-30 Celtrix Pharmaceuticals, Inc. Null IGF for the treatment of cancer
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
EP1191941A4 (de) * 1999-06-21 2006-12-13 Murdoch Childrens Res Inst Methode der prophylaxe und/oder behandlung von erkrankungen
US6468290B1 (en) 2000-06-05 2002-10-22 Scimed Life Systems, Inc. Two-planar vena cava filter with self-centering capabilities
CA2422625A1 (en) * 2000-09-19 2002-03-28 Bioexpertise, Llc Method for use of igf-binding protein for selective sensitization of target cells in vivo
US6841386B2 (en) 2001-04-10 2005-01-11 Viacell, Inc. Modulation of primary stem cell differentiation using an insulin-like growth factor binding protein
US6887851B2 (en) * 2001-09-18 2005-05-03 Bioexpertise, Llc IGF-binding protein-derived peptide
US6861406B2 (en) * 2001-09-18 2005-03-01 Bioexpertise, Llc IGF-binding protein-derived peptide
US6914049B2 (en) 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
US20050148509A1 (en) * 2003-07-09 2005-07-07 The University Of Iowa Research Foundation Binding proteins as chemotherapy
US7625390B2 (en) 2004-04-16 2009-12-01 Cook Incorporated Removable vena cava filter
US10022212B2 (en) 2011-01-13 2018-07-17 Cook Medical Technologies Llc Temporary venous filter with anti-coagulant delivery method

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
ATE116335T1 (de) * 1987-12-24 1995-01-15 Gropep Pty Ltd Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2).
GB8826451D0 (en) * 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
EP0556344B1 (de) * 1991-01-08 2003-08-13 Chiron Corporation Insulinartigen wachstumsfaktor bindendes protein
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response

Also Published As

Publication number Publication date
CA2172158A1 (en) 1995-03-30
US5527776A (en) 1996-06-18
JPH09507832A (ja) 1997-08-12
ATE226958T1 (de) 2002-11-15
EP1238674A2 (de) 2002-09-11
ES2241906T3 (es) 2005-11-01
DE69434403D1 (de) 2005-07-14
AU7731494A (en) 1995-04-10
EP1238674B1 (de) 2005-06-08
DE69431631D1 (de) 2002-12-05
WO1995008567A1 (en) 1995-03-30
EP0726911A1 (de) 1996-08-21
DE69434403T2 (de) 2006-05-04
EP0726911B1 (de) 2002-10-30
EP1238674A3 (de) 2002-10-23
AU688793B2 (en) 1998-03-19
EP0726911A4 (de) 1997-02-26
DE69431631T2 (de) 2003-07-31

Similar Documents

Publication Publication Date Title
DE69434403D1 (de) Behandlung von immunologischen und hematologischen störungen mit igfbp allein oder als komplex mit igf
DE10399007I1 (de) Osteoinduktive Mittel
GR3007092T3 (de)
ATE187889T1 (de) Vorbeugung und behandlung der peripheren neuropathie
EP0236684A3 (en) Galanthamine or analogues thereof for treating alzheimer's disease
RU94046291A (ru) Способ профилактики и лечения периферической невропатии, композиция, содержащая инсулин-подобный фактор роста i
GR3015490T3 (en) Composition and method for the treatment of osteoporosis in mammals.
EP0341302A4 (en) Methods for prevention and treatment of mucositis with granulocyte colony stimulating factor
ES2174852T3 (es) Metodo para el tratamiento sistemico de estados catabolicos y lesiones sistemicas de tejidos.
DE69211899D1 (de) Siloxan modifizierter Polyester zur Behandlung von Fasern
ES2144527T3 (es) Metodo para el tratamiento de disfunciones en la reproduccion.
DE3688528D1 (de) Optische analoge datenverarbeitungsanordnungen zur behandlung von bipolaren und komplexen daten.
NO903322D0 (no) Fremgangsmaate for behandling av huder og huder oppnaadd derved.
DE59202695D1 (de) Mittel zur Oberflächenbehandlung von Dentalteilen, insbesondere Schleif-, Polier- und/oder Strahlmittel.
DE3768595D1 (de) Einrichtung zur kontrolle und behandlung von gegenstaenden.
DE58902466D1 (de) Acyl-carnitin zur behandlung und zur verhuetung von virusinfektionen.
ATE100100T1 (de) Oxadiazole zur verwendung in der behandlung von dementia senilis.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1238674

Country of ref document: EP

REN Ceased due to non-payment of the annual fee